<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248855</url>
  </required_header>
  <id_info>
    <org_study_id>KAN-101-01</org_study_id>
    <nct_id>NCT04248855</nct_id>
  </id_info>
  <brief_title>Assessment of KAN-101 in Celiac Disease (ACeD)</brief_title>
  <official_title>A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anokion SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study of KAN-101 in patients with celiac disease. The study has two parts:&#xD;
&#xD;
        1. Part A - first in human study in which patients receive a single dose of KAN-101&#xD;
&#xD;
        2. Part B - patients will receive three doses of either KAN-101 or placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of&#xD;
      KAN-101 in patients with celiac disease on a gluten free diet (GFD).&#xD;
&#xD;
      An overview of the two parts and proposed dose groups is given below:&#xD;
&#xD;
        1. Part A (SAD): Patients will receive a single dose of KAN-101.&#xD;
&#xD;
        2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher</measure>
    <time_frame>Up to 28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC last)</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAN-101</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_label>MAD Cohort 7</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_label>MAD Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 18 to 70 years inclusive&#xD;
&#xD;
          2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase&#xD;
             IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology&#xD;
             consistent with â‰¥ Marsh Type II or with evidence of villous atrophy&#xD;
&#xD;
          3. Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes)&#xD;
&#xD;
          4. Has followed a GFD for &gt; 12 months immediately prior to study entry&#xD;
&#xD;
          5. Negative or weak positive for tTG-IgA and negative or weak positive for DGP-IgA/IgG&#xD;
             during screening&#xD;
&#xD;
          6. Male or female. Females of childbearing potential must use at least 2 acceptable birth&#xD;
             control methods&#xD;
&#xD;
          7. Capable of understanding and complying with protocol requirements&#xD;
&#xD;
          8. Patient understands and has signed the informed consent form&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Refractory celiac disease&#xD;
&#xD;
          2. Selective IgA deficiency&#xD;
&#xD;
          3. Positive for HLA-DQ8 (DQA1*03, DQB1*0302)&#xD;
&#xD;
          4. Previous treatment with tolerance-inducing therapies for celiac disease&#xD;
&#xD;
          5. Known wheat allergy&#xD;
&#xD;
          6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure&#xD;
&#xD;
          7. Uncontrolled or significant medical conditions (including active infections or chronic&#xD;
             hepatitis) which, in the opinion of the Investigator, preclude participation&#xD;
&#xD;
          8. History of dermatitis herpetiformis&#xD;
&#xD;
          9. Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCP Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel International- EPCU Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celiac Disease Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Double blind</keyword>
  <keyword>Multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

